Journal: Nature reviews. Clinical oncology
This publication reviews advances in the systemic treatment of hormone-sensitive prostate cancer (HSPC), moving beyond traditional androgen-deprivation therapy (ADT) alone.
It highlights the benefit of adding:
- Androgen receptor pathway inhibitors (ARPIs)
- Docetaxel
- Radiotherapy in selected patient subgroups
Emerging therapies under evaluation for metastatic HSPC include:
- AKT inhibitors
- Radioligand therapies
- PARP inhibitors
The review emphasizes the impact of modern imaging modalities like PSMA PET in detecting metastases earlier and refining treatment decisions.
Key topics covered are:
- Personalized management strategies for non-metastatic and metastatic HSPC
- Patient selection for docetaxel
- Choice of ARPI
- Use of radiotherapy
- Approaches to mitigate treatment toxicity